IMPEL PHARMACEUTICALS INC (IMPL)
US45258K1097 - Common Stock
We assign a fundamental rating of 1 out of 10 to IMPL. IMPL was compared to 588 industry peers in the Biotechnology industry. IMPL may be in some trouble as it scores bad on both profitability and health. IMPL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
IMPL had negative earnings in the past year.
In the past year IMPL has reported a negative cash flow from operations.
1.2 Ratios
With a Return On Assets value of -204.40%, IMPL is not doing good in the industry: 92.36% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.4% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-194.15%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMPL has a better Gross Margin (57.30%) than 80.07% of its industry peers.
The Profit Margin and Operating Margin are not available for IMPL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMPL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMPL has been increased compared to 1 year ago.
IMPL has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -18.82, we must say that IMPL is in the distress zone and has some risk of bankruptcy.
IMPL has a Altman-Z score of -18.82. This is amonst the worse of the industry: IMPL underperforms 89.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.82 |
ROIC/WACCN/A
WACC10.15%
2.3 Liquidity
IMPL has a Current Ratio of 0.27. This is a bad value and indicates that IMPL is not financially healthy enough and could expect problems in meeting its short term obligations.
IMPL's Current ratio of 0.27 is on the low side compared to the rest of the industry. IMPL is outperformed by 97.01% of its industry peers.
A Quick Ratio of 0.21 indicates that IMPL may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.21, IMPL is doing worse than 97.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.21 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.50% over the past year.
Looking at the last year, IMPL shows a very strong growth in Revenue. The Revenue has grown by 264.05%.
EPS 1Y (TTM)3.5%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q21.1%
Revenue 1Y (TTM)264.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q135%
3.2 Future
IMPL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.33% yearly.
IMPL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.95% yearly.
EPS Next Y64.5%
EPS Next 2Y34.33%
EPS Next 3Y23.19%
EPS Next 5Y21.33%
Revenue Next Year128.2%
Revenue Next 2Y101.18%
Revenue Next 3Y85.83%
Revenue Next 5Y87.95%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
IMPL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMPL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IMPL's earnings are expected to grow with 23.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.33%
EPS Next 3Y23.19%
5. Dividend
5.1 Amount
No dividends for IMPL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
IMPEL PHARMACEUTICALS INC
NASDAQ:IMPL (12/15/2023, 7:00:03 PM)
After market: 0.22 -0.02 (-8.75%)0.2411
-0.17 (-41.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.76M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -204.4% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.3% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.43
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.27 | ||
| Quick Ratio | 0.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)3.5%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y64.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)264.05%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y